Ramelteon: application withdrawn. Ramelteon in insomnia: withdrawal of marketing application in patients' best interests.
The European Committee for Medicinal Products for Human Use (CHMP) has issued a negative opinion on the use of the melatonin receptor agonist ramelteon in insomnia, due to its unfavourable risk-benefit balance. In France, melatonin itself is licensed for use in this indication.